<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39982">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585895</url>
  </required_header>
  <id_info>
    <org_study_id>20140316</org_study_id>
    <secondary_id>2015-001343-37</secondary_id>
    <nct_id>NCT02585895</nct_id>
  </id_info>
  <brief_title>Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment</brief_title>
  <official_title>A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled
      low density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future
      apheresis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apheresis avoidance at the end of randomized therapy, defined as no apheresis at week 5 and week 6</measure>
    <time_frame>Week 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apheresis avoidance at the end of randomized therapy, defined as no apheresis at week 5 and week 6</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in low density lipoprotein-cholesterol</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non-high density lipoprotein-cholesterol</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total cholesterol/high density lipoprotein-cholesterol ratio</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>evolocumab (AMG145)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive evolocumab (AMG 145) every 2 weeks (Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Density Lipoprotein Cholesterol (LDL-C) Apheresis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will continue apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>evolocumab (AMG 145)</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>evolocumab (AMG145)</arm_group_label>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Density Lipoprotein Cholesterol (LDL-C) Apheresis</intervention_name>
    <description>Subjects will continue apheresis at the same schedule, every week or every two weeks, as prior to study entry</description>
    <arm_group_label>Low Density Lipoprotein Cholesterol (LDL-C) Apheresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, ≥ 18 years of age

          -  Subject has been receiving regular apheresis for LDL-C lowering for at least 3 months
             immediately prior to lipid screening and has a treatment goal of LDL-C &lt; 100 mg/dL
             (2.6 mmol/L), and has been receiving LDL-C apheresis during the last ≥ 4 weeks prior
             to lipid screening at regular QW or Q2W schedule and with no changes in apheresis
             type

          -  Subject is receiving lipid-lowering pharmacological background therapy which includes
             a high-intensity statin dose (moderate-intensity statin dose with attestation that a
             higher dose is not appropriate for the subject) unless the subject has a history of
             statin intolerance

          -  Lipid-lowering therapy status (ie, any therapy for lowering lipids, including
             apheresis type and frequency) must be unchanged for ≥ 4 weeks prior to LDL-C
             screening

          -  Pre-apheresis LDL-C is ≥ 100 mg/dL (≥ 2.6 mmol/L) and ≤ 190 mg/dL (≤ 4.9 mmol/L) at
             screening

          -  Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) at screening.

        Exclusion criteria:

          -  Known homozygous familial hypercholesterolemia

          -  Missing any apheresis session is medically contraindicated or inappropriate

          -  Stopping apheresis would be inappropriate in the opinion of the investigator even if
             LDL-C is controlled to &lt; 100 mg/dL with other therapies

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization.

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grandville</city>
        <state>Michigan</state>
        <zip>49418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harefield</city>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penarth</city>
        <zip>CF64 2XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>October 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL-C Apheresis</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Elevated Cholesterol</keyword>
  <keyword>High Cholesterol</keyword>
  <keyword>PCSK9 mutations</keyword>
  <keyword>Severe Familial Hypercholesterolemia</keyword>
  <keyword>evolocumab</keyword>
  <keyword>Repatha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
